Source: Pharmacy Times articles
Daratumumab combined with VRd significantly improved outcomes in transplant-ineligible/transplant deferred patients with newly diagnosed multiple myeloma.
Read More
Recent Content
- Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
- Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
- Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
- A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
- Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
- Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
- Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
- Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
- Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
- The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma